The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Table 1 Characteristics of subjects with ESCC

Gender	Male	61 (83.6%)
Gender	Female	12 (16.4%)
Age	Mean ± SD, (y)	69.0 ± 8.2
Weight	Mean ± SD, (kg)	53.9 ± 8.8
Height	Mean ± SD, (cm)	161.1 ± 8.0
Performance status	0	18 (24.7%)
	1	39 (53.4%)
	2	16 (21.9%)
	3	0 (0.0%)
eGFR	Mean ± SD, (ml/min/1.73 m2)	78.0 ± 20.5
Tumor location (primary site)	Ce	9 (12.3%)
	Ut	11 (15.1%)
	Mt	35 (47.9%)
	Lt	18 (24.7%)
	EGJ	0 (0.0%)
Number of pre-CRT biopsy samples	Median with range, (n)	2 (1–6)
Histological type	Well differentiated SCC	10 (13.7%)
	Moderately differentiated SCC	54 (74.0%)
	Poorly differentiated SCC	9 (12.3%)
	Basaloid SCC	0 (0.0%)
Depth of invasion	cTis	0 (0.0%)
	cT1a	0 (0.0%)
	cT1b	15 (20.5%)
	cT2	9 (12.3%)
	cT3	22 (30.1%)
	cT4a	12 (16.4%)
	cT4b	15 (20.5%)
Tumor size	Median with range, (cm)	5.0 (1.0–10.5)
Lymph node metastasis	cN0	24 (32.9%)
	cN1	12 (16.4%)
	cN2	32 (43.8%)
	cN3	5 (6.8%)
Distant metastasis	cM0	63 (86.3%)
	cM1-lym	10 (13.7%)
	cM1-hematogenous or (pleural/peritoneal) dissemination	0 (0.0%)
Clinical stage, TNM 8th	0	0 (0.0%)
	I (cT1b)	14 (19.2%)
	II	8 (11.0%)
	III	16 (21.9%)
	IVA	25 (34.2%)
	IVB (cM1-lym)	10 (13.7%)
	IVB with hematogenous metastasis or (pleural/peritoneal) dissemination	0 (0.0%)
SLFN11 expression	Mean ± SD, (H-score)	74.6 ± 77.7
Follow up periods	Median (range)	23 (12–44)

Abbreviations: SD standard deviation, eGFR estimated glomerular filtration rate, CE cervical esophagus, Ut upper thoracic esophagus, Mt middle thoracic esophagus, Lt lower thoracic esophagus, EGJ esophago-gastric junction, cT1a tumor invasion to the muscularis mucosa, cT1b tumor invasion to the submucosa, cT2 tumor invasion to the muscularis propria, cT3 tumor invasion to the adventitia, cT4a tumor invasion to the pleura, pericardium, azygos vein, diaphragm, or peritoneum, cT4b tumor invasion to other adjacent structures, such as the aorta, vertebral body, or trachea, cN0 no regional lymph node metastasis, cN1 metastasis in 1–2 regional lymph nodes, cN2 metastasis in 3–6 regional lymph nodes, cN3 metastasis in 7 or more regional lymph nodes, cM0 no distant metastasis, cM1-lym distant lymph node metastasis, CRT chemoradiotherapy, H-score histo-score
All values indicate n (%) unless otherwise indicated

ISSN: 1471-2407